Drawing for XALQORY

USPTO serial 85313459

XALQORY

Reviewed by CopyMark Law Group

Status 605
Filing date
Status date
Registration date
Examiner
LORENZO, GEORGE M
Law office

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with XALQORY?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations for the treatment of oncological diseases and disordersABANDONED

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Nov 9, 2011MAB5ABANDONMENT NOTICE MAILED - AFTER PUBLICATION
Nov 9, 2011ABN5ABANDONMENT - AFTER PUBLICATION
Nov 3, 2011EXARTEAS EXPRESS ABANDONMENT RECEIVED
Sep 20, 2011NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Sep 20, 2011PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Aug 16, 2011PREVLAW OFFICE PUBLICATION REVIEW COMPLETED
Aug 12, 2011CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER
Aug 12, 2011XAECEXAMINER'S AMENDMENT ENTERED
Aug 11, 2011ALIEASSIGNED TO LIE
Aug 11, 2011GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Aug 11, 2011GNEAEXAMINERS AMENDMENT E-MAILED
Aug 11, 2011CNEAEXAMINERS AMENDMENT -WRITTEN
Aug 8, 2011DOCKASSIGNED TO EXAMINER
May 11, 2011NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 9, 2011NWAPNEW APPLICATION ENTERED

Frequently asked questions

Related guidance